|Articles|August 1, 2001

August 2001
Volume 7
Issue 8

Estimated Coronary Heart Disease Attributable to Insulin Resistance in Populations With and Without Type 2 Diabetes Mellitus

Author(s)David R. Strutton, MPH, Paul E. Stang, PhD, John R. Erbey, PhD

Download PDF: Estimated Coronary Heart Disease Attributable to Insulin Resistance in Populations With and Without Type 2 Diabetes Mellitus

Articles in this issue

almost 25 years ago

Article

Hospice Use in Medicare Managed Care and Fee-for-Service Systems

almost 25 years ago

Article

A Randomized Trial of Nurse Specialist Home Care for Women with High-Risk Pregnancies: Outcomes and Costs

almost 25 years ago

Article

Prevalence, Costs, and Treatment of Alzheimer's Disease and Related Dementia: A Managed Care Perspective

almost 25 years ago

Article

Healthcare Ethics Committees and Managed Care

almost 25 years ago

Article

Managed Care Can Make a Difference: The Need for Care at the End of Life

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Estimated Coronary Heart Disease Attributable to Insulin Resistance in Populations With and Without Type 2 Diabetes Mellitus

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Diagnosing Alzheimer's Disease Agitation: Triggers, Care Specialties, and the Role of Primary Care

FDA Approves First Autoinjector for At-Home IV-Equivalent Diuresis

Defining Alzheimer's Disease Agitation: Diagnostic Criteria, Symptoms, and Disease Course

Small Workflow Changes Close Big Gaps in CKM Screening

Nipocalimab Improves gMG Outcomes Across East Asian Subgroup